Literature DB >> 12067294

Modification of bacteraemia by specific antibodies and relation with mortality in a pneumococcal mouse sepsis model.

J Yuste1, I Jado, M J Giménez, L Aguilar, F Molero, A Fenoll, J Casal.   

Abstract

The relationship between mortality and the bacteraemic profile was investigated in a pneumococcal (serotype 6B) sepsis BALB/c mouse model where animals received protection by specific hyperimmune serum. A single intraperitoneal dose of hyperimmune serum obtained from mice immunized with the heat-inactivated strain was administered (non-diluted or diluted to 1/4 or to 1/16) to 5-mice study groups 1 h prior to intraperitoneal inoculation with the infective inoculum (3.57 x 108 cfu/ml). Blood cultures were performed daily over 15 days, with 8 microl of blood being collected from the tail vein; the samples were resuspended in Todd-Hewitt broth containing 10% trisodium citrate and plated onto blood agar for colony counting. Animals included in the control group received placebo (PBS). Mortality was 100% in control animals within the first 48 h. Hyperimmune serum decreased and delayed mortality in a dose-related trend, producing 100%, 80%, 60% and 40% survival rates at 72, 96, 144 and 360 h, with non-diluted serum. Bacteraemic profiles with maximum colony counts > or =5 x 107 cfu/ml in blood during the follow-up period were related to > or =65% probability of death, regardless of the serum dilution administered.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12067294      PMCID: PMC1906260          DOI: 10.1046/j.1365-2249.2002.01860.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  10 in total

1.  Streptococcus pneumoniae in community-acquired respiratory tract infections in Spain: the impact of serotype and geographical, seasonal and clinical factors on its susceptibility to the most commonly prescribed antibiotics. The Spanish Surveillance Group for Respiratory Pathogens.

Authors:  F Marco; E Bouza; J García-de-Lomas; L Aguilar
Journal:  J Antimicrob Chemother       Date:  2000-10       Impact factor: 5.790

Review 2.  Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain: update (1990 to 1996).

Authors:  A Fenoll; I Jado; D Vicioso; A Pérez; J Casal
Journal:  J Clin Microbiol       Date:  1998-12       Impact factor: 5.948

3.  Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae.

Authors:  D E Briles; M J Crain; B M Gray; C Forman; J Yother
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

4.  Quantitative relationship between anticapsular antibody measured by enzyme-linked immunosorbent assay or radioimmunoassay and protection of mice against challenge with Streptococcus pneumoniae serotype 4.

Authors:  D M Musher; B Johnson; D A Watson
Journal:  Infect Immun       Date:  1990-12       Impact factor: 3.441

5.  Serum samples from infants vaccinated with a pneumococcal conjugate vaccine, PncT, protect mice against invasive infection caused by Streptococcus pneumoniae serotypes 6A and 6B.

Authors:  E Saeland; H Jakobsen; G Ingolfsdottir; S T Sigurdardottir; I Jonsdottir
Journal:  J Infect Dis       Date:  2000-12-08       Impact factor: 5.226

6.  Effective combination therapy for invasive pneumococcal pneumonia with ampicillin and intravenous immunoglobulins in a mouse model.

Authors:  L De Hennezel; F Ramisse; P Binder; G Marchal; J M Alonso
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

7.  Minimum protective serum concentrations of pneumococcal anti-capsular antibodies in infant rats.

Authors:  A M Stack; R Malley; C M Thompson; L Kobzik; G R Siber; R A Saladino
Journal:  J Infect Dis       Date:  1998-04       Impact factor: 5.226

8.  The mouse peritonitis model: present and future use.

Authors:  N Frimodt-Møller
Journal:  J Antimicrob Chemother       Date:  1993-05       Impact factor: 5.790

Review 9.  Return to the past: the case for antibody-based therapies in infectious diseases.

Authors:  A Casadevall; M D Scharff
Journal:  Clin Infect Dis       Date:  1995-07       Impact factor: 9.079

10.  Prophylaxis and treatment of pneumococcal bacteremia by immune globulin intravenous in a mouse model.

Authors:  D S Chudwin
Journal:  Clin Immunol Immunopathol       Date:  1989-01
  10 in total
  6 in total

1.  Combined effect of specific antibodies (as serotherapy or preimmunization) and amoxicillin doses in treatment of Streptococcus pneumoniae sepsis in a mouse model.

Authors:  J Yuste; A Fenoll; J Casal; M J Giménez; L Aguilar
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

2.  Changing trends in etiology of bacteremia in patients with cancer.

Authors:  A Safdar; G H Rodriguez; M Balakrishnan; J J Tarrand; K V I Rolston
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-08       Impact factor: 3.267

Review 3.  Animal models of Streptococcus pneumoniae disease.

Authors:  Damiana Chiavolini; Gianni Pozzi; Susanna Ricci
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

4.  Enhanced in vivo activity of cefditoren in pre-immunized mice against penicillin-resistant S. pneumoniae (serotypes 6B, 19F and 23F) in a sepsis model.

Authors:  Fabio Cafini; Jose Yuste; Maria-Jose Giménez; David Sevillano; Lorenzo Aguilar; Luis Alou; Elisa Ramos-Sevillano; Martha Torrico; Natalia González; Ernesto García; Pilar Coronel; Jose Prieto
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

5.  Fully human monoclonal antibodies from antibody secreting cells after vaccination with Pneumovax®23 are serotype specific and facilitate opsonophagocytosis.

Authors:  Kenneth Smith; Jennifer J Muther; Angie L Duke; Emily McKee; Nai-Ying Zheng; Patrick C Wilson; Judith A James
Journal:  Immunobiology       Date:  2012-09-03       Impact factor: 3.144

6.  Cefditoren and ceftriaxone enhance complement-mediated immunity in the presence of specific antibodies against antibiotic-resistant pneumococcal strains.

Authors:  Elisa Ramos-Sevillano; Cinthya Rodríguez-Sosa; Fabio Cafini; Maria-Jose Giménez; Ana Navarro; David Sevillano; Luis Alou; Ernesto García; Lorenzo Aguilar; Jose Yuste
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.